Buyer for oncology software company in Europe

Company to buy

• Size: Mid-sized business
• Revenue: 5 – 50 million EUR
• Location of the target company: Europe
• CFIE ITB389

Overview of buyer for oncology software company in Europe

The company is a leading global provider of oncology research and development services. Predominately, it is dedicated to advancing cancer drug development through scientific excellence and innovative solutions. Essentially, it has clinical sites, laboratories, and a scientific team strategically distributed around the world. Further, they support studies globally, generating insights faster and more efficiently. Notably, the company is backed by a software VC fund and is currently looking to acquire an oncology software company to further enhance its capabilities.

Profile (strategy) of buyer for oncology software company in Europe

Overall, the company’s mission is to improve patients’ lives by meeting the challenges of cancer drug development with innovative solutions. In total, their strategy is built on four core values: Scientific excellence, teamwork, integrity, and respect. These values drive every aspect of their operations and partnerships. Altogether, they aim to become an integral part of their clients’ scientific teams, ensuring the delivery of high-quality data on time, every time. As an illustration, their corporate citizenship is reflected in their dedication to improving patient quality of life. Moreover, they support pharmaceutical and biotechnology companies in bringing new therapies and potential cures to market faster.

Activities and services of buyer for oncology software company in Europe

The company offers a comprehensive suite of activities and services aimed at accelerating drug development processes. For instance, their in vivo modeling includes a vast collection of preclinical models. Primarily, for assessing novel anticancer agents across various therapeutic modalities, including cell therapy and immune-oncology agents. In addition, they provide characterized syngeneic and humanized mouse models for testing innovative immune-oncology therapeutics.

Their ex vivo proprietary platforms are developed by expert R&D scientists to deliver insights and solve complex preclinical industry issues. In particular, these platforms include high-throughput screening and unique assays to assess mechanisms like cytotoxicity, proliferation, and infiltration. Furthermore, they also offer cell line assays, hematological VitroScreen, TumorGraft3D platform, and co-culture assays for comprehensive cancer research.

The company’s clinical specialty testing includes high-complexity flow cytometry, plate-based assays, immunohistochemistry, and next-generation sequencing. Even more, they provide unrivaled expertise in study design, sample logistics, and data analysis, ensuring superior results for patient samples. Their validated and fully customizable assays and collection kits offer optimum flexibility and operational readiness for clinical trials.

Highlights of buyer for oncology software company in Europe

• Global reach and rapid insight generation: With a global presence and distributed scientific team, the company supports studies worldwide, ensuring faster and more efficient generation of insights.
• Comprehensive service portfolio: Their activities and services cover a wide range of preclinical and clinical research needs, from in vivo modeling to ex vivo platforms and clinical specialty testing.
• Advanced preclinical models: The company boasts a robust collection of over 1,000 solid tumor and hematological models, providing an unparalleled resource for preclinical assessments.
• Proprietary platforms: Their proprietary platforms, offer unique capabilities for evaluating therapeutic efficacy and understanding cancer biology.
• High-quality clinical testing: The company’s clinical specialty testing labs operate at the highest standards, offering GCLP-compliant platforms, CLIA accreditation, and customizable assays.

This company’s comprehensive approach, from preclinical models to clinical specialty testing, positions it as an ideal partner for pharmaceutical and biotechnology companies. Especially those looking to accelerate their oncology drug development processes. Above all, their ongoing pursuit of acquiring an oncology software company underscores their commitment to leveraging technology and innovation. Ultimately, to further their mission of improving patients’ lives through scientific excellence.

More information on this buyer for oncology software company in Europe

Please get in touch if you are interested in learning more about this buyer for oncology software company in Europe. For more it other companies for sale please visit the section it other companies for sale. For other it other buyers, please visit the section it other companies wanted. If you are instead interested in companies for sale, please visit the companies for sale section. For buyers, please visit the section companies wanted.